(Total Views: 413)
Posted On: 05/05/2019 1:00:59 AM
Post# of 155780
As things currently stand a reduction in new cases is occurring but is at a near stasis. Unknowing transmittals, lapses in drug use and drug resistance will keep things as they are.
What the future holds with the addition of leronlimab. With viral rates as low as .4 copies per ml on leronlimab transmission rates should be further reduced. No drug resistance. Extended coverage for any lapse in drug usage.
This will not be the elimination of HIV due to CXCR5 variant and other factors. But leronlimab can produce a dramatic reduction in new cases and a better quality of life for existing cases.
Leronlimab is a game changer and that will eventually be reflected in the share price.
What the future holds with the addition of leronlimab. With viral rates as low as .4 copies per ml on leronlimab transmission rates should be further reduced. No drug resistance. Extended coverage for any lapse in drug usage.
This will not be the elimination of HIV due to CXCR5 variant and other factors. But leronlimab can produce a dramatic reduction in new cases and a better quality of life for existing cases.
Leronlimab is a game changer and that will eventually be reflected in the share price.
(0)
(0)
